Over the previous couple of decades, the incidence of chronic diseases like diabetes, arteria coronaria disease, chronic obstructive pulmonary disease (COPD), asthma, hepatitis, arthritis, and cancer has increased significantly in major regions across the world. Owing to this result active pharmaceutical ingredient (API) market has huge market demand.
Moreover, API due to geopolitical situations and therefore the demand to cut back dependence on China for API products. Furthermore, governments of the many countries have formulated plans and granted incentives to market the assembly of API.
However, the high manufacturing cost of APIs is one among the main challenges faced by market players. Manufacturers often need to make costly investments for improvements in their manufacturing facilities to make sure compliance with standards like the cGMP. This includes the renovation of production facilities, inculcating familiarity with qualification requirements and processes, and building a dossier of product efficacy and safety tests that meet the wants of regulatory authorities. Furthermore, the prices of obtaining regulatory approvals are relatively higher for firms with small volumes. The chemical synthesis of arthropod genus additionally usually needs dear and uncommon building blocks and raw materials, which any adds to API producing prices.
| Report Metric | Details |
| Market size available for years | 2023–2030 |
| Base year considered | 2023 |
| Forecast period | 2024–2030 |
| Forecast unit | Value (USD Million) |
| Segments covered | Synthetic Type, Drug Type, Application and Region |
| Regions covered | North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA) |
| Companies covered | Boehringer Ingelheim, Merck & Co., Inc., Dr. Reddy’s Laboratories Ltd., AbbVie, Inc., Bristol-Myers Squibb Company, Cipla, Inc., Teva Pharmaceutical Industries Ltd., Albemarle Corporation, Viatris Inc., Aurobindo Pharma, Sun Pharmaceutical Industries Ltd. |
Covid-19 Impact on Active Pharmaceutical Ingredient (API) Market:
In addition, this world Market study offers associate comprehensive analysis of this COVID-19 pandemic impact on the market growth and its influence on the long run growth of the worldwide Market. The recently printed report demonstrates the elevation at intervals the demand for the tending sector. The tending makers have skilled future additionally as short term impact which contains offer shortages, panic shopping for, and stocking, regulation changes as short-run whereas approval delays and attainable trend variations in consumption may well be perceived as long-run impacts of COVID-19 on the health and pharmaceutical market.
The increasing want for a cure has pushed immunogen analysis and manufacturers to the limit. Additionally to this, panic conditions have already spurred the demand for many tending product and services that area unit mentioned intimately throughout this report. Moreover, the impact of this pandemic on overall market revenue for the bottom year 2020 and its projection up to 2027 is provided well during this report.
Active Pharmaceutical Ingredient (API) Market Segment Overview
By synthesis type, what is more, the enlargement of the biotech section is commonly attributed to high investments at intervals the biotechnology and biopharmaceutical sectors.
By drug type, the innovative arthropod genus section accounted for the largest share of the worldwide active pharmaceutical ingredients market in 2023. Inflated agency approvals for innovative molecular entities, the high worth of innovative arthropod genus as compared to the generic medication, inflated specialize in R&D by the conceiver API corporations area unit the factors contributory towards the enlargement of the innovative arthropod genus section.
Based on application, in 2023, the medical specialty section is foretold to register the best CAGR throughout the forecast amount. Growth throughout this market section is driven by the increasing demand for extremely potent arthropod genus (HPAPIs) for the treatment of cancer.
Market Analysis, Insights and Forecast – By Synthesis Type
· Synthetic
· Biotech
Market Analysis, Insights and Forecast – By Drug Type
· Generic
· Innovative
· Branded
Market Analysis, Insights and Forecast – By Application
· Cardiology
· Pulmonology
· Oncology
· Ophthalmology
· Neurology
· Orthopaedic
· Other
Active Pharmaceutical Ingredient (API) Market Regional Overview
Region-wise, in terms of regions, North America accounted the major market share in the forecast period. This is often attributed to the rising epidemiology of cancer, alongside other lifestyle-induced diseases, thus encouraging the R&D activities, thereby boosting the market growth.
Active Pharmaceutical Ingredient (API) Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Active Pharmaceutical Ingredient (API) Market Competitor overview
Some key developments and strategies adopted by manufacturers in the Active Pharmaceutical Ingredient (API) are highlighted below.
· In 2020, Boehringer Ingelheim acquired Northern Biologics; these results strengthen to Boehringer Ingelheim’s oncology product portfolio.
Active Pharmaceutical Ingredient (API) Market, Key Players
· Boehringer Ingelheim
· Merck & Co., Inc.
· Dr. Reddy’s Laboratories Ltd.
· AbbVie, Inc.
· Bristol-Myers Squibb Company
· Cipla, Inc.
· Teva Pharmaceutical Industries Ltd.
· Albemarle Corporation
· Viatris Inc.
· Aurobindo Pharma
· Sun Pharmaceutical Industries Ltd.
Frequently Asked Questions (FAQ) :
Q1. What is the total CAGR expected to be recorded for the Active Pharmaceutical Ingredient (API) market during the forecast period?
Q2. Which segment is projected to hold the largest share in the Active Pharmaceutical Ingredient (API) Market?
Q3. What are the driving factors for the Active Pharmaceutical Ingredient (API) market? ?
Q4. Which Segments are covered in the Active Pharmaceutical Ingredient (API) market report??
Q5. Which are the prominent players offering Active Pharmaceutical Ingredient (API)?
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Active Pharmaceutical Ingredient (API) Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Synthesis Type
- 5.2.1. Synthetic
- 5.2.2. Biotech
- 5.3. Market Analysis, Insights and Forecast – By Drug Type
- 5.3.1. Generic
- 5.3.2. Innovative
- 5.3.3. Branded
- 5.4. Market Analysis, Insights and Forecast – By Application
- 5.4.1. Cardiology
- 5.4.2. Pulmonology
- 5.4.3. Oncology
- 5.4.4. Ophthalmology
- 5.4.5. Neurology
- 5.4.6. Orthopaedic
- 5.4.7. Other
- 5.5. Market Analysis, Insights and Forecast – By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America, Middle East, and Africa
6. North America Active Pharmaceutical Ingredient (API) Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Synthesis Type
- 6.2.1. Synthetic
- 6.2.2. Biotech
- 6.3. Market Analysis, Insights and Forecast – By Drug Type
- 6.3.1. Generic
- 6.3.2. Innovative
- 6.3.3. Branded
- 6.4. Market Analysis, Insights and Forecast – By Application
- 6.4.1. Cardiology
- 6.4.2. Pulmonology
- 6.4.3. Oncology
- 6.4.4. Ophthalmology
- 6.4.5. Neurology
- 6.4.6. Orthopaedic
- 6.4.7. Other
- 6.5. Market Analysis, Insights and Forecast – By Country
- 6.5.1. U.S.
- 6.5.2. Canada
7. Europe Active Pharmaceutical Ingredient (API) Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Business Mode
- 7.2.1. Liquids Synthesis Type Equipment
- 7.2.2. Solids Synthesis Type Equipment
- 7.2.3. Semi-Solids Synthesis Type Equipment
- 7.2.4. Others
- 7.3. Market Analysis, Insights and Forecast – By Synthesis Type
- 7.3.1. Primary Synthesis Type Equipment
- 7.3.2. Secondary Synthesis Type
- 7.3.3. Labelling and Serialization Equipment
- 7.4. Market Analysis, Insights and Forecast – By Country
- 7.4.1. UK
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Italy
- 7.4.5. Spain
- 7.4.6. Russia
- 7.4.7. Rest of Europe
8. Asia Pacific Active Pharmaceutical Ingredient (API) Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Synthesis Type
- 8.2.1. Synthetic
- 8.2.2. Biotech
- 8.3. Market Analysis, Insights and Forecast – By Drug Type
- 8.3.1. Generic
- 8.3.2. Innovative
- 8.3.3. Branded
- 8.4. Market Analysis, Insights and Forecast – By Application
- 8.4.1. Cardiology
- 8.4.2. Pulmonology
- 8.4.3. Oncology
- 8.4.4. Ophthalmology
- 8.4.5. Neurology
- 8.4.6. Orthopaedic
- 8.4.7. Other
- 8.5. Market Analysis, Insights and Forecast – By Country
- 8.5.1. China
- 8.5.2. India
- 8.5.3. Japan
- 8.5.4. Australia
- 8.5.5. South East Asia
- 8.5.6. Rest of Asia Pacific
9. Latin America, Middle East, and Africa Active Pharmaceutical Ingredient (API) Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Synthesis Type
- 9.2.1. Synthetic
- 9.2.2. Biotech
- 9.3. Market Analysis, Insights and Forecast – By Drug Type
- 9.3.1. Generic
- 9.3.2. Innovative
- 9.3.3. Branded
- 9.4. Market Analysis, Insights and Forecast – By Application
- 9.4.1. Cardiology
- 9.4.2. Pulmonology
- 9.4.3. Oncology
- 9.4.4. Ophthalmology
- 9.4.5. Neurology
- 9.4.6. Orthopaedic
- 9.4.7. Other
- 9.5. Market Analysis, Insights and Forecast – By Country
- 9.5.1. Brazil
- 9.5.2. Saudi Arabia
- 9.5.3. UAE
- 9.5.4. Rest of LAMEA
10. Competitive Analysis
- 10.1. Company Market Share Analysis, 2018
- 10.2. Key Industry Developments
- 10.3. Company Profile
- 10.4. Boehringer Ingelheim
- 10.4.1. Business Overview
- 10.4.2. Segment 1 & Service Offering
- 10.4.3. Overall Revenue
- 10.4.4. Geographic Presence
- 10.4.5. Recent Development
- 10.5. Merck & Co., Inc.
- 10.6. Dr. Reddy’s Laboratories Ltd.
- 10.7. AbbVie, Inc.
- 10.8. Bristol-Myers Squibb Company
- 10.9. Cipla, Inc.
- 10.10. Teva Pharmaceutical Industries Ltd.
- 10.11. Albemarle Corporation
- 10.12. Viatris Inc.
- 10.13. Aurobindo Pharma
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
